Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Prochlorperazine: Dopamine D2 Antagonist for Oncology & Anti

    2026-05-04

    Prochlorperazine: Atomic Mechanisms and Translational Benchmarks

    Executive Summary: Prochlorperazine (CAS No. 58-38-8) is a phenothiazine derivative and a potent dopamine D2 receptor antagonist, used widely as an antiemetic and in cancer research (source: DOI). It also targets histamine and muscarinic receptors, contributing to side effect and efficacy profiles (source: product_spec). In vitro, it inhibits melanoma cell proliferation with EC₅₀ values of 3.76±0.14 μM in COLO829 and 2.90±0.17 μM in C32 cells (source: product_spec). Clinically, it is administered at 5–10 mg for antiemetic therapy (source: product_spec). APExBIO supplies Prochlorperazine (SKU: A8508) for research use, supporting robust protocols in oncology, virology, and neuropharmacology (source: product_spec).

    Biological Rationale

    Prochlorperazine is classified as a typical antipsychotic of the phenothiazine class and is primarily distinguished by its high-affinity antagonism at dopamine D2 receptors. Dopaminergic signaling is integral to the regulation of nausea and vomiting, as well as to certain oncogenic processes in melanoma cells (source: naloxonecatalog.com article). By blocking D2 receptors, Prochlorperazine disrupts the emetogenic signaling in the chemoreceptor trigger zone and impairs signaling pathways required for melanoma cell proliferation. The molecule’s antagonism of histamine H1/H2, muscarinic acetylcholine, and adrenergic α1/α2 receptors extends its pharmacodynamic spectrum but also mediates its side effect profile (source: product_spec).

    Mechanism of Action of Prochlorperazine

    Prochlorperazine exerts its primary pharmacological effects via potent and selective inhibition of dopamine D2 receptors. This action abrogates dopaminergic stimulation in central emetic pathways, providing robust antiemetic efficacy (source: DOI). In melanoma and other cancer models, Prochlorperazine modulates microphthalmia-associated transcription factor (MITF) and tyrosinase, leading to reduced cell proliferation and migration (source: product_spec). The compound also inhibits clathrin-mediated endocytosis, altering membrane lipid rafts and exhibiting documented antiviral properties (source: MSH-RIF article). These mechanisms underpin its multipurpose use in oncology, virology, and neuropharmacology.

    Evidence & Benchmarks

    • Prochlorperazine inhibits dopamine D2 receptors, providing antiemetic effects in clinical and preclinical models (source: DOI).
    • In vitro, Prochlorperazine demonstrates inhibition of melanoma cell proliferation: EC₅₀ = 3.76±0.14 μM (COLO829); EC₅₀ = 2.90±0.17 μM (C32) (source: product_spec).
    • Antiemetic clinical doses typically range from 5–10 mg orally or intravenously (source: product_spec).
    • Effective concentrations for in vitro wound healing and migration assays are 1–4 μM (source: product_spec).
    • As an antiviral, Prochlorperazine blocks clathrin-mediated endocytosis, limiting viral entry in cell-based systems (source: MSH-RIF article).
    • Prochlorperazine is insoluble in water but soluble in DMSO (≥16.5 mg/mL) and ethanol (≥58.5 mg/mL), and must be stored at -20°C (source: product_spec).
    • Major adverse events include extrapyramidal symptoms and rare neuroleptic malignant syndrome; it is contraindicated in severe cardiovascular disease (source: product_spec).

    For a broader mechanistic context, see this review, which expands on Prochlorperazine's antiviral and melanoma-specific actions. This article provides more granular, quantitative protocol guidance than previous overviews.

    Applications, Limits & Misconceptions

    Prochlorperazine is widely used in antiemetic therapy, especially for chemotherapy-induced nausea, migraine, and acute mountain sickness (source: product_spec). Its role in melanoma research is supported by in vitro data demonstrating EC₅₀-level inhibition of cell proliferation and migration. The compound is also being explored as an antiviral agent due to its ability to block endocytosis, though these findings remain largely preclinical (source: MSH-RIF article). For cancer research, Prochlorperazine is not a cytotoxic agent but modulates key transcriptional regulators, making it valuable in combination or mechanistic studies.

    Common Pitfalls or Misconceptions

    • Prochlorperazine is not suitable as a first-line antipsychotic due to a high risk of extrapyramidal side effects (source: product_spec).
    • It should not be used in patients with severe cardiovascular disease or known hypersensitivity (source: product_spec).
    • Its antiviral activity is documented in vitro but not established for clinical treatment of viral infections; use in this context is experimental (source: MSH-RIF article).
    • It does not induce direct cytotoxicity in most cancer settings; its anti-cancer effects are via pathway modulation (source: product_spec).
    • Solubility limitations require use of organic solvents (DMSO or ethanol) for in vitro assays (source: product_spec).

    For an in-depth analysis of melanoma mechanisms, see this article, which this review extends by providing specific EC₅₀ values, solubility, and safety workflows for APExBIO's A8508 product.

    Workflow Integration & Parameters

    Protocol Parameters

    • Wound healing assay | 1–4 μM | Melanoma migration studies | Effective for cell migration inhibition without cytotoxicity | product_spec
    • Cell proliferation/viability assay | 1–10 μM | Melanoma and other cancer cell lines | EC₅₀ profiling and mechanistic pathway studies | product_spec
    • Antiviral entry inhibition | 1–10 μM | Cell-based viral entry models | Inhibits clathrin-mediated endocytosis in vitro | workflow_recommendation
    • Antiemetic therapy (clinical) | 5–10 mg orally/IV | Human, clinical | Standard dose for nausea, vomiting, migraine | product_spec
    • Compound storage | -20°C | All applications | Maintains compound stability and potency | product_spec
    • Solubility in DMSO | ≥16.5 mg/mL | Stock preparation | Ensures adequate stock for cell culture | product_spec
    • Solubility in ethanol | ≥58.5 mg/mL | Stock preparation | Alternative solvent for specific protocols | product_spec

    For troubleshooting and advanced optimization, APExBIO provides additional guidance with the A8508 kit. For comparison of protocol choices, see this mechanistic insight article, which this review updates with newly benchmarked EC₅₀ and workflow details.

    Conclusion & Outlook

    Prochlorperazine (APExBIO SKU: A8508) is a validated dopamine D2 receptor antagonist with multifaceted utility in antiemetic therapy, melanoma research, and antiviral studies. Quantitative benchmarks (EC₅₀, solubility, dose) support its integration into robust in vitro and clinical workflows (source: product_spec). Its mechanism of action—spanning dopamine, histamine, muscarinic, and adrenergic receptor antagonism—enables translational applications but also imposes safety boundaries. The evidence base is strongest for antiemetic and melanoma uses, with antiviral applications remaining preclinical. As the research landscape advances, Prochlorperazine’s protocolized use will continue to support reproducible discovery in cancer and virology.

    For the latest, see Prochlorperazine A8508 at APExBIO, or compare mechanistic coverage in this foundational antiemetic review, which this article updates by providing machine-readable protocol and benchmark structures.